Eli Lilly's Mounjaro is as effective as old drugs in reducing the risk of heart disease

Eli Lilly's diabetes drug Mounjaro failed to meet expectations in a trial, not demonstrating superior effects in preventing heart attacks and strokes compared to its older drug Trulicity. The research results provided by Eli Lilly indicate that Mounjaro can effectively reduce the risk of heart attacks, strokes, and cardiovascular death, but it did not show significant superiority over Trulicity. Bloomberg analyst Michael Shah stated, "The trial results did not mention its superiority, and Eli Lilly tested this as well," adding that the results "are unlikely to be accepted by the market."